PRGL493|cas:2479378-45-3|西域试剂

PRGL493,99.64%

产品编号：Bellancom-139180| CAS NO：2479378-45-3| 分子式：C₂₅H₂₁N₇O₂| 分子量：451.48

本网站销售的所有产品仅用于工业应用或者科学研究等非医疗目的,不可用于人类或动物的临床诊断或者治疗,非药用,非食用，

货号	包装	价格	库存与货期	购买量	操作
Bellancom-139180		￥1800.00	杭州北京（现货）
Bellancom-139180		￥2900.00	杭州北京（现货）

增值税发票√顺丰快递√订货电话：18601927057

PRGL493

产品介绍

PRGL493 是一种高效、选择性的长链酰基辅酶 a 合成酶 4 (ACSL4) 抑制剂。PRGL493 在乳腺和前列腺细胞及动物模型中均可阻断细胞增殖和肿瘤生长。PRGL493 用于癌症研究。

生物活性

PRGL493 is a potent and selective long-chain acyl-CoA synthetase 4 (ACSL4) inhibitor. PRGL493 blocks cell proliferation and tumor growth in both breast and prostate cellular and animal models. PRGL493 is used for cancer research.

体外研究

Acyl-CoA synthetase 4 (ACSL4) is an isoenzyme of the fatty acid ligase-coenzyme-A family taking part in arachidonic acid metabolism and steroidogenesis.
PRGL493 ([³H]-AA (0.5 µCi/ml in serumfree medium) for 3 h; 48 hours) signifcantly inhibits the activity of ACSL4 in all three cell lines (MDA-MB-231, PC-3 and MA-10 Leydig cells), as evidenced by a reduction in AA-CoA levels.But PRGL493 has no effects on ACSL4 protein expression.
PRGL493 (20-100 μM; 72 hours) inhibits the proliferation of highly aggressive breast and prostate cancer cells at an IC₅₀ of 23 µM and 27 µM, respectively.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

体内研究

PRGL493 (intraperitoneal injection; 250 μg/Kg; 43 and 34 consecutive days) decreases tumor volumes and inhibits tumor growth. Additionally, this compound results in a decrease in Ki67 protein expression and increases ER and AR expression in breast and prostate xenograft tumors, respectively.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	MDA-MB-231 or PC-3 cell suspensions mixed with Matrigel Matrix in a 3/1 dilution are injected into the right fank of NLAE:NIH(S)Fox1^nu mice, aged 7-8 weeks
Dosage:	250 μg/kg
Administration:	Intraperitoneal injection; 250 μg/kg; 43 and 34 consecutive days
Result:	Inhibited tumor growth in vivo models

体内研究

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	MDA-MB-231 or PC-3 cell suspensions mixed with Matrigel Matrix in a 3/1 dilution are injected into the right fank of NLAE:NIH(S)Fox1^nu mice, aged 7-8 weeks
Dosage:	250 μg/kg
Administration:	Intraperitoneal injection; 250 μg/kg; 43 and 34 consecutive days
Result:	Inhibited tumor growth in vivo models

性状

Solid

溶解性数据

In Vitro:

DMSO : 5 mg/mL (11.07 mM; ultrasonic and warming and heat to 60°C)

配制储备液

浓度溶剂体积质量	1 mg	5 mg	10 mg

1 mM	2.2149 mL	11.0747 mL	22.1494 mL
5 mM	0.4430 mL	2.2149 mL	4.4299 mL
10 mM	0.2215 mL	1.1075 mL	2.2149 mL

请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。
储备液的保存方式和期限：-80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)。-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。

In Vivo:

请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液，再依次添加助溶剂：

——为保证实验结果的可靠性，澄清的储备液可以根据储存条件，适当保存；体内实验的工作液，建议您现用现配，当天使用；以下溶剂前显示的百
分比是指该溶剂在您配制终溶液中的体积占比；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的方式助溶

1.

请依序添加每种溶剂： 10% DMSO 40% PEG300 5% Tween-80 45% saline
Solubility: ≥ 1.25 mg/mL (2.77 mM); Clear solution

此方案可获得 ≥ 1.25 mg/mL (2.77 mM，饱和度未知) 的澄清溶液。
以 1 mL 工作液为例，取 100 μL 12.5 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中，混合均匀；向上述体系中加入50 μL Tween-80，混合均匀；然后继续加入 450 μL生理盐水定容至 1 mL。
将 0.9 g 氯化钠，完全溶解于 100 mL ddH₂O 中，得到澄清透明的生理盐水溶液
2.

请依序添加每种溶剂： 10% DMSO 90% (20% SBE-β-CD in saline)
Solubility: ≥ 1.25 mg/mL (2.77 mM); Clear solution

此方案可获得 ≥ 1.25 mg/mL (2.77 mM，饱和度未知) 的澄清溶液。
以 1 mL 工作液为例，取 100 μL 12.5 mg/mL 的澄清 DMSO 储备液加到 900 μL 20% 的 SBE-β-CD 生理盐水水溶液中，混合均匀。
将 2 g 磺丁基醚 β-环糊精加入 5 mL 生理盐水中，再用生理盐水定容至 10 mL，完全溶解，澄清透明
3.

请依序添加每种溶剂： 10% DMSO 90% corn oil
Solubility: ≥ 1.25 mg/mL (2.77 mM); Clear solution

此方案可获得 ≥ 1.25 mg/mL (2.77 mM，饱和度未知) 的澄清溶液，此方案不适用于实验周期在半个月以上的实验。
以 1 mL 工作液为例，取 100 μL 12.5 mg/mL 的澄清 DMSO 储备液加到 900 μL玉米油中，混合均匀。